Elizabeth Ann Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses some of the top papers presented at the ASCO-SITC Symposium and how these presentations will affect clinical practice.
Marie-Andrée Forget, PhD, of The University of Texas MD Anderson Cancer Center, discusses study findings on the impact of checkpoint blockade prior to adoptive cell therapy using tumo...
Roy S. Herbst, MD, PhD, of the Yale Cancer Center, discusses immunotherapy as a standard of care in lung cancer, critical biomarkers, and scientifically guided combination treatment, ...
Stephen Gottschalk, MD, of Baylor College of Medicine and Texas Children’s Hospital, discusses combining CAR T cells with checkpoint blockade or targeted treatments to improve their a...
Holger N. Lode, MD, of the University of Greifswald, discusses in German the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO an...
Lawrence Fong, MD, of the University of California, San Francisco, discusses combination immunotherapy, now approved in melanoma, and the trials underway to explore other indications.
